Market closedNon-fractional
Verrica Pharmaceuticals/VRCA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Verrica Pharmaceuticals
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
Ticker
VRCA
Sector
Healthcare
Trading on
NASDAQ
Industry
Pharmaceuticals
Headquarters
West Chester, United States
Employees
100
Website
www.verrica.com
VRCA Metrics
BasicAdvanced
$308M
Market cap
-
P/E ratio
-$1.75
EPS
1.77
Beta
-
Dividend rate
Price and volume
Market cap
$308M
Beta
1.77
Financial strength
Current ratio
3.169
Quick ratio
2.919
Long term debt to equity
3,012.865
Total debt to equity
3,079.841
Interest coverage (TTM)
-11.90%
Management effectiveness
Return on assets (TTM)
-69.22%
Return on equity (TTM)
-243.35%
Valuation
Price to revenue (TTM)
37.586
Price to book
205.98
Price to tangible book (TTM)
205.98
Price to free cash flow (TTM)
-6.171
Growth
Revenue change (TTM)
3.18%
Earnings per share change (TTM)
192.99%
3-year revenue growth (CAGR)
-9.44%
3-year earnings per share growth (CAGR)
9.19%
What the Analysts think about VRCA
Analyst Ratings
Majority rating from 6 analysts.
VRCA Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$3.8M
100.00%
Net income
-$20M
-17.48%
Profit margin
-534.21%
-58.74%
VRCA Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.24
-$0.54
-$0.53
-$0.44
-
Expected
-$0.21
-$0.36
-$0.53
-$0.40
-$0.41
Surprise
14.18%
49.52%
0.38%
11.28%
-
VRCA News
AllArticlesVideos
Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc.
GlobeNewsWire·4 weeks ago
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York
GlobeNewsWire·2 months ago
Verrica Pharmaceuticals Announces Amendment to Company's Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Verrica Pharmaceuticals stock?
Verrica Pharmaceuticals (VRCA) has a market cap of $308M as of July 27, 2024.
What is the P/E ratio for Verrica Pharmaceuticals stock?
The price to earnings (P/E) ratio for Verrica Pharmaceuticals (VRCA) stock is 0 as of July 27, 2024.
Does Verrica Pharmaceuticals stock pay dividends?
No, Verrica Pharmaceuticals (VRCA) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Verrica Pharmaceuticals dividend payment date?
Verrica Pharmaceuticals (VRCA) stock does not pay dividends to its shareholders.
What is the beta indicator for Verrica Pharmaceuticals?
Verrica Pharmaceuticals (VRCA) has a beta rating of 1.77. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Verrica Pharmaceuticals stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.